Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-04-19
2011-04-19
Bowman, Amy (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C514S04400A
Reexamination Certificate
active
07928220
ABSTRACT:
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of stromal cell-derived factor-1 (SDF-1) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in SDF-1 gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating or that mediate RNA interference (RNAi) against SDF-1 gene expression. Such small nucleic acid molecules are useful, for example, in providing compositions for treatment of traits, diseases and conditions that can respond to modulation of SDF-1 expression in a subject, such as ocular disease, cancer and proliferative diseases and any other disease, condition, trait or indication that can respond to the level of SDF-1 in a cell or tissue.
REFERENCES:
patent: 5814620 (1998-09-01), Robinson et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 5998206 (1999-12-01), Cowsert
patent: 2002/0151693 (2002-10-01), Breaker et al.
patent: 2005/0020521 (2005-01-01), Rana
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2359180 (2000-03-01), None
patent: WO90/14090 (1990-11-01), None
patent: WO94/01550 (1994-01-01), None
patent: WO99/32619 (1999-07-01), None
patent: WO99/49029 (1999-09-01), None
patent: WO99/50461 (1999-10-01), None
patent: WO00/44895 (2000-08-01), None
patent: WO00/44914 (2000-08-01), None
patent: WO00/49035 (2000-08-01), None
patent: WO01/36646 (2001-05-01), None
patent: WO01/96584 (2002-03-01), None
patent: WO02/22636 (2002-03-01), None
patent: WO02/44321 (2002-06-01), None
patent: WO03/064626 (2003-08-01), None
Anderson et al. “Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance,” Oligonucleotides 13(5):303-312 (2003).
Elbashir et al. “Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs,” Methods 26 (2):199-213 (2002).
Elbashir et al. “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,” Nature 411(6836):494-498 (2001).
Elbashir et al. “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophilamelanogaster Embryo Lysate,” EMBO J. 20(23):6877-6888 (2001).
Elbashir et al. “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,” Genes Dev. 15(2):188-200 (2001).
Fire et al. “Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans,” Nature 391:806-811 (1998).
Futami et al. “Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against Bcl-2,” Nucleic Acids Research Supplement 2:251-252 (2002).
International Search Report mailed on Mar. 31, 2005 for PCT/US04/16390, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05028, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05346, 1 page.
Leirdal et al. “Gene Silencing in Mammalian Cells by Preformed Small RNA Duplexes,” Biochemical and Biophysical Research Communications 295:744-748 (2002).
Lin et al. “A Novel mRNA-cDNA Interference Phenomenon for Silencing Bcl-2 Expression in Human LNCaP Cells,” Biochemical and Biophysical Research Communications 281:639-644 (2001).
Tuschl et al. “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,” Molecular Interventions 295(3):158-167 (2002).
Tuschl et al. “Targeted mRNA Degradation by Double-Stranded RNA in Vitro,” Genes and Development 13 (24):3191-3197 (1999).
Office Action mailed on Feb. 4, 2008 for U.S. Appl. No. 10/444,853, 37 pages.
Office Action mailed on Jul. 1, 2008 for U.S. Appl. No. 11/499,520, 13 pages.
Office Action mailed on Oct. 8, 2008 for U.S. Appl. No. 11/499,529, 34 pages.
Office Action mailed on Nov. 14, 2008 for U.S. Appl. No. 11/502,875, 14 pages.
Office Action mailed on Apr. 8, 2009 for U.S. Appl. No. 11/502,876, 31 pages.
Office Action mailed on Jan. 26, 2009 for U.S. Appl. No. 11/676,124, 15 pages.
Office Action mailed on Feb. 3, 2009 for U.S. Appl. No. 10/693,059, 7 pages.
Office Action mailed on Jul. 2, 2008 for U.S. Appl. No. 10/757,803, 26 pages.
Office Action mailed on Apr. 16, 2009 for U.S. Appl. No. 12/105,010, 24 pages.
Office Action mailed Feb. 14, 2008 in U.S. Appl. No. 11/140,328, 34 pages.
Request for Continued Examination with 1.114(c) Amendment filed Oct. 31, 2007 in U.S. Appl. No. 11/140,328, 25 pages.
Final Office Action mailed Oct. 29, 2007 in U.S. Appl. No. 11/140,328, 18 pages.
1.111 Amendment filed Aug. 16, 2007 in U.S. Appl. No. 11/140,328, 28 pages.
Office Action mailed Feb. 16, 2007 in U.S. Appl. No. 11/140,328, 16 pages.
1.111 Amendment filed Sep. 23, 2009 in U.S. Appl. No. 12/169,519, 8 pages.
Office Action mailed Apr. 9, 2009 in U.S. Appl. No. 12/169,519, 22 pages.
Bertrand, et al., Biochemical & Biophysical Research Communications, vol. 296, pp. 1000-1004 (2002).
Braasch, et al., Biochemistry 41(14), pp. 4503-4510 (2002).
Olie, et al., Biochimica et Biophysica Acta, vol. 1576. pp. 101-109 (2002).
Hammond, et al., Nature Reviews: Genetics, vol. 2, pp. 110-119 (2001).
Parrish, et al., Molecular Cell, vol. 6, pp. 1077-1087 (2000).
Beigelman Leonid
McSwiggen James
Bowman Amy
Ginkel Laura M.
Merck Sharp & Dohme Corp.
Muthard David A.
LandOfFree
RNA interference mediated inhibition of stromal cell-derived... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNA interference mediated inhibition of stromal cell-derived..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNA interference mediated inhibition of stromal cell-derived... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2633894